watch
NPS Pharmaceuticals, Inc.

NPS Pharmaceuticals, Inc.

Sector: Pharmaceutical Preparations Region: NJ, United States


: | Nasdaq: NPSP


NPS Pharmaceuticals is a biopharmaceutical company focused on bringing orphan products to patients with rare disorders and few, if any, therapeutic options. The company’s lead product, Gattex® 0.05 mg/kg/d (Teduglutide [rDNA origin]) for Injection is FDA-approved for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. NPS is also developing Natpara® (rhPTH[1-84]) for the treatment of adult hypoparathyroidism and expects to submit its Biologic License Application (BLA) to the FDA in mid-2013. NPS's earlier stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria (ADHH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, Kyowa Hakko Kirin, and Takeda GmbH.

Investor Calendar

Latest Media

Warning! Third-party cookies must be enabled to view SlideShare presentations. ×

Having trouble?

Investor Slide Deck

NPS Pharmaceuticals, Inc. video

Investor Slide Deck

Executives

Peter G. Tombros, Chairman of the Board
Mr. Tombros has served as a director since 1998 and in January 2008 was appointed chairman of the board. Since 2005, Mr. Tombros has served as professor and executive in residence in the Eberly College of Science BS/MBA Program at Pennsylvania State University. Prior to that, he was chair of the board and chief executive officer of VivoQuest, a private biopharmaceutical company. From 1994 until June 2001, Mr. Tombros served as president, chief executive officer, and director of Enzon Pharmaceuticals, a publicly held biopharmaceutical company. Prior to joining Enzon, Mr. Tombros spent 25 years with Pfizer Inc., a global healthcare company, in a variety of senior management positions including vice president of marketing, senior vice president and general manager of the Roerig Pharmaceuticals Division, executive vice president of Pfizer Pharmaceuticals Division, director of Pfizer Pharmaceuticals Division, vice president of corporate strategic planning and vice president, corporate officer, Pfizer Inc.Mr. Tombros serves on the board of directors of Cambrex Corporation, a publicly held life sciences company focused on small molecule therapeutics. Mr. Tombros received BS and MS degrees from Pennsylvania State University and an MBA degree from the University of Pennsylvania Wharton Graduate School of Business.
Michael W. Bonney, Director
Mr. Bonney has served as a director since January 2005. Mr. Bonney has served since June 2003 as the president and chief executive officer and as a member of the Board of Directors of Cubist Pharmaceuticals, Inc., a public biopharmaceutical company. From January 2002 to June 2003, he served as its president and chief operating officer. From 1995 to 2001, he held various positions at Biogen, Inc., a public biopharmaceutical company, including vice president, sales and marketing from 1999 to 2001. Prior to that, Mr. Bonney held various positions in sales, marketing and strategic planning at Zeneca Pharmaceuticals, ending his 11-year career there serving as National Business Director. Mr. Bonney has a BA in Economics from Bates College. Mr. Bonney is a trustee of the Beth Israel Deaconess Medical Center, Chair of the Board of Trustees of Bates College, and a member of the Board of Directors of Pharmaceutical Research and Manufacturers of America (PhRMA), a trade association representing research-based pharmaceutical and biotechnology companies in the United States.
Colin Broom, MD, Director
Dr. Broom has been a director since July 2009. Since May 2004, he has served as vice president and chief scientific officer of ViroPharma Incorporated, a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists in a hospital setting. At ViroPharma, Dr. Broom is responsible for the leadership of all research and development and medical affairs activities. Prior to ViroPharma, Dr. Broom served as vice president of clinical development and medical affairs, Europe, for Amgen. Previously, he was vice president of clinical development for Hoechst Marion Roussel (now sanofi-aventis) and for 14 years worked for Glaxo and then SmithKline Beecham (now GlaxoSmithKline) in a range of leadership positions of increasing responsibility, including head of global oncology and vice president of CNS/GI. Dr. Broom holds a Bachelor of Science degree in Pharmacology from University College, London and a Bachelor of Medicine and Bachelor of Surgery degree from St. George's Hospital Medical School, London. He is a Member of the Royal College of Physicians and a Fellow of the Faculty of Pharmaceutical Medicine of the UK Colleges of Physicians.
Georges Gemayel, PhD, Director
Dr. Gemayel has been a director since February 2012.  Dr. Gemayel has held senior positions at pharmaceutical and biotechnology companies over his career of more than 25 years.  He is currently chairman of Syndexa Pharmaceuticals and chairman of Vascular Magnetics Inc.  He previously served as executive chairman of FoldRx Pharmaceuticals, Inc., president and chief executive officer of Altus Pharmaceuticals, Inc., executive vice president of Genzyme Corporation, vice president of Roche Specialty Care, and general manager of Roche Portugal.  Dr. Gemayel previously served as a director at Adolor Corporation, and chairman of FoldRx Pharmaceuticals, Inc.  Dr. Gemayel received his doctorate in pharmacy at Saint Joseph University in Beirut, Lebanon and earned a Ph.D. in pharmacology at Paris-Sud University in France.
Pedro Granadillo, Director
Mr. Granadillo has been a director since November 2010. Mr. Granadillo, who is now retired, has more than 30 years of pharmaceutical industry experience. At Eli Lilly and Company, he served as senior vice president of human resources, manufacturing and quality. As the company's top executive for human resources, manufacturing and quality, Mr. Granadillo was a member of the executive committee and responsible for managing an extensive network of pharmaceutical manufacturing facilities and for policies affecting the company's global workforce of more than 43,000 employees. Mr. Granadillo received a BS in industrial engineering from Purdue University. He currently serves as a director of Dendreon Corporation, Haemonetics Corporation and Nile Therapeutics, and previously served as a director of Noven Pharmaceuticals and First Indiana Bank.
James G. Groninger, Director
Mr. Groninger has served as a director since 1988. In February 2011, Mr. Groninger became CEO of TIPeR Development Corporation, a private biotechnology company licensing technology from the University of Pennsylvania to commercialize a technology using RNA to change cellular phenotypes. In February 2002, Mr. Groninger was appointed chief executive officer of LBS Technologies, Inc., a private biotechnology company focusing on RNA amplification and cellular therapy. Mr. Groninger is president of The Bay South Company, a Richmond, Virginia-based provider of financial advisory and investment banking services he founded in January 1995. From 1988 through 1994, he served as a managing director, investment banking division, of PaineWebber Incorporated. Mr. Groninger is a member of the board of directors of Cygne Designs, Inc., a publicly held company, and Layton BioScience, Inc., LBS Technologies, Inc. and Expression Pathology, Inc., private biotechnology companies. Mr. Groninger received a BS from Yale University and an MBA degree from Harvard Business School, and has been certified with CPA and CFA designations.
Francois Nader, MD, President and Chief Executive Officer
Francois Nader, MD, has been president, chief executive officer and a member of the Board of Directors of NPS Pharmaceuticals since 2008. During his tenure, Dr. Nader transformed NPS into a leading global biotechnology company focused on treatments for patients with rare disorders in gastroenterology and endocrinology. NPS’ lead product, Gattex for Short Bowel Syndrome, was approved in Europe and the US in 2012. NPS plans to file its second product, Natpara for Hypoparathyroidism, in the US in 2013. Dr. Nader is a 30-year veteran of the healthcare industry. He joined NPS in 2006 as chief medical and commercial officer and was promoted to chief operating officer in 2007. Previously, he was a venture partner at Care Capital. Dr. Nader served on the North America Leadership Team of Aventis and its predecessor companies and held a number of executive positions including senior vice-president, integrated healthcare markets and North America medical and regulatory affairs. Prior, Dr. Nader led the global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc.
Dr. Nader currently serves as chairman of the Board of Trustees for BioNJ, New Jersey’s trade organization representing the biotechnology industry, and Board member of the New Jersey Chamber of Commerce. He formerly served on the Board of the Healthcare Institute of New Jersey and Noven Pharmaceuticals. Dr. Nader earned his French Doctorate in Medicine from St. Joseph University (Lebanon) and his Physician Executive MBA from the University of Tennessee.
Rachel R. Selisker, CPA, Director
Ms. Selisker has served as a director since January 2005. Ms. Selisker is president of Seamark Advisors LLC and has provided financial consulting and appraisal services in the healthcare sector since June 2007. She served from March 2006 to June 2007 as chief financial officer of AAIPharma Inc., a privately held contract research organization. From January 2001 to March 2006, she served as a managing director in the Raleigh, North Carolina, office of Thompson Clive & Partners Inc., a venture capital firm based in London, where she focused on the life sciences sector. She served from July 1987 to February 2000 as the chief financial officer, and from February 2000 to January 2001 as senior vice president, global shared services, of Quintiles Transnational Corp., a publicly held global contract research organization. Ms. Selisker has also served as director of Quintiles Transnational Corp. from November 1995 to February 2000. Ms. Selisker was a supervisor and staff accountant with the national accounting firm of Oppenheim, Appel, Dixon & Co. in Raleigh, North Carolina, from 1981 to 1987. She is a certified public accountant with extensive public accounting experience from 1976, when she graduated with her accounting degree from Wake Technical College in Raleigh, North Carolina. In 1987, she joined Quintiles. She has also served as a director of Labopharm, Inc. since November 2008

News & Analysis